WO2014052613A3 - Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers - Google Patents

Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers Download PDF

Info

Publication number
WO2014052613A3
WO2014052613A3 PCT/US2013/061950 US2013061950W WO2014052613A3 WO 2014052613 A3 WO2014052613 A3 WO 2014052613A3 US 2013061950 W US2013061950 W US 2013061950W WO 2014052613 A3 WO2014052613 A3 WO 2014052613A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
next generation
generation sequencing
genetic testing
related cancers
Prior art date
Application number
PCT/US2013/061950
Other languages
French (fr)
Other versions
WO2014052613A2 (en
Inventor
David R. HOUT
Eric Dahlhauser
Adam Platt
Original Assignee
Insight Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Genetics, Inc. filed Critical Insight Genetics, Inc.
Priority to US14/431,430 priority Critical patent/US20150240301A1/en
Priority to CA 2886397 priority patent/CA2886397A1/en
Publication of WO2014052613A2 publication Critical patent/WO2014052613A2/en
Publication of WO2014052613A3 publication Critical patent/WO2014052613A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Disclosed are methods, assays, and compositions for detecting the presence of a kinase inhibitor resistance. The disclosed method and primer panels work with any method for detecting nucleic acid variation in a sample including, but not limited to next generation sequencing.
PCT/US2013/061950 2012-09-26 2013-09-26 Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers WO2014052613A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/431,430 US20150240301A1 (en) 2012-10-05 2013-09-26 Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
CA 2886397 CA2886397A1 (en) 2012-09-26 2013-09-26 Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261705825P 2012-09-26 2012-09-26
US61/705,825 2012-09-26
US201261710455P 2012-10-05 2012-10-05
US61/710,455 2012-10-05

Publications (2)

Publication Number Publication Date
WO2014052613A2 WO2014052613A2 (en) 2014-04-03
WO2014052613A3 true WO2014052613A3 (en) 2014-06-12

Family

ID=50389131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/061950 WO2014052613A2 (en) 2012-09-26 2013-09-26 Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Country Status (2)

Country Link
CA (1) CA2886397A1 (en)
WO (1) WO2014052613A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7036594B2 (en) * 2014-07-14 2022-03-15 ウニベルジテート チューリッヒ プロレクトラット エムエンベー Means and Methods for Identifying Patients with BRAF-Positive Cancer as Non-Responders to BRAF Inhibitors and Responders to MAPK / ERK Inhibitors
US11136584B2 (en) * 2015-11-04 2021-10-05 Duke University Splice-switching oligonucleotides and methods of use
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN111793675B (en) * 2019-12-11 2023-05-23 杭州迪安医学检验中心有限公司 Nucleic acid sequence for EGFR gene 18 exon G719X mutation detection, kit and application thereof
CA3214540A1 (en) * 2021-04-22 2022-10-27 Pasi A. Janne Compositions and methods for treating cancer
CN117844933A (en) * 2024-03-07 2024-04-09 上海复迪生生命科学有限公司 Multiplex PCR primer group for detecting lung tumor related gene variation and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090546A (en) * 1994-11-11 2000-07-18 Medinnova Sf Method for the detection of Ras oncogenes, in particular the K-ras oncogene
US20110081651A1 (en) * 2005-06-28 2011-04-07 Genentech, Inc. Egfr and kras mutations
WO2011054030A1 (en) * 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20110212456A1 (en) * 2007-03-13 2011-09-01 Amgen K-ras and B-raf mutations and anti-EGFr antibody therapy
WO2011104695A2 (en) * 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of kras mutation in exon 2 by allele specific real time quantitative pcr (as-qpcr)
US20110269640A1 (en) * 2008-10-21 2011-11-03 Guangzhou Surexam Bio-Tech Co., Ltd. PROBES FOR DETECTING MUTATIONS OF kRas GENE, LIQUICHIP AND DETECTION METHODS THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090546A (en) * 1994-11-11 2000-07-18 Medinnova Sf Method for the detection of Ras oncogenes, in particular the K-ras oncogene
US20110081651A1 (en) * 2005-06-28 2011-04-07 Genentech, Inc. Egfr and kras mutations
US20110212456A1 (en) * 2007-03-13 2011-09-01 Amgen K-ras and B-raf mutations and anti-EGFr antibody therapy
US20110269640A1 (en) * 2008-10-21 2011-11-03 Guangzhou Surexam Bio-Tech Co., Ltd. PROBES FOR DETECTING MUTATIONS OF kRas GENE, LIQUICHIP AND DETECTION METHODS THEREOF
WO2011054030A1 (en) * 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2011104695A2 (en) * 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of kras mutation in exon 2 by allele specific real time quantitative pcr (as-qpcr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAKER ET AL.: "Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.", BR J CANCER., vol. 104, no. 3, 1 February 2011 (2011-02-01), pages 4887495 *
DE REYNIES ET AL.: "KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.", J CLIN ONCOL, vol. 26, no. 13, 1 May 2008 (2008-05-01), pages 2228 - 30 *
ROSS ET AL.: "Whole cancer genome sequencing by next-generation methods.", AM J CLIN PATHOL, vol. 136, no. 4, October 2011 (2011-10-01), pages 527 - 39 *

Also Published As

Publication number Publication date
CA2886397A1 (en) 2014-04-03
WO2014052613A2 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
WO2014052613A3 (en) Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
EP2746395A4 (en) Primer set, method for amplifying target nucleic acid sequence using same, and method for detecting mutated nucleic acid using same
WO2012129363A3 (en) Single cell nucleic acid detection and analysis
GB2526736A (en) Methods, compositions, and kits for nucleic acid analysis
GB201317477D0 (en) Methods, compositions and kits for determing the presence/absnece of a variant nucleic acid sequence
WO2012167142A3 (en) Enzyme quantification
MX338296B (en) Compositions and methods for quantifying a nucleic acid sequence in a sample.
WO2012134602A3 (en) Methods and systems for sequencing long nucleic acids
EP2262911A4 (en) Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
WO2014182528A3 (en) Multiplex labeling of molecules by sequential hybridization barcoding
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
BR112014020422A2 (en) method for determining the presence or absence of a target polynucleotide in a sample, isolated or partzime primer oligonucleotide, isolated double stranded nucleic acid duplex, multi-component nucleic acid enzyme, nucleic acid complex, use of mnazyme and kit
WO2014004609A3 (en) Rapid assays for t-cell activation by rna measurements using flow cytometry
WO2011153354A8 (en) Methods and kits for in situ detection of nucleotide sequences
WO2012174378A3 (en) Methods and materials for assessing allelic imbalance
WO2012033537A8 (en) Benchmarks for normal cell identification
EP2314680A4 (en) Method for amplification of target nucleic acid sequence, method for detection of mutation by using the method, and reagents for use in the methods
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
UA115321C2 (en) Methods and compositions for analyzing ahasl genes in wheat
BR112014005505A2 (en) isolated polynucleotide substrate for a catalytic nucleic acid enzyme, method for detecting the presence of at least one target, use of the isolated polynucleotide substrate and kit
MX363880B (en) Cooperative primers, probes, and applications thereof.
WO2013090386A3 (en) Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample
GB201021499D0 (en) Detection of quantative genetic differnces
WO2012145516A3 (en) Methods and kits for quantitative determination of total organic acid content in a coolant
WO2012106711A3 (en) A method for detecting chromosome structure and gene expression simultaneously in single cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13840295

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2886397

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14431430

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 13840295

Country of ref document: EP

Kind code of ref document: A2